NASDAQ:SLN Silence Therapeutics (SLN) Stock Price, News & Analysis $18.65 -0.20 (-1.06%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$18.30▼$19.1650-Day Range$15.53▼$21.7452-Week Range$6.15▼$27.72Volume181,932 shsAverage Volume268,243 shsMarket Capitalization$558.19 millionP/E RatioN/ADividend YieldN/APrice Target$57.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Silence Therapeutics alerts: Email Address Silence Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside206.7% Upside$57.20 Price TargetShort InterestHealthy1.17% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.20Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.55) to ($1.38) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.77 out of 5 starsMedical Sector379th out of 910 stocksPharmaceutical Preparations Industry169th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingSilence Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSilence Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Silence Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.17% of the outstanding shares of Silence Therapeutics have been sold short.Short Interest Ratio / Days to CoverSilence Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Silence Therapeutics has recently decreased by 37.54%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSilence Therapeutics does not currently pay a dividend.Dividend GrowthSilence Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLN. Previous Next 1.8 News and Social Media Coverage News SentimentSilence Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Silence Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for SLN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Silence Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.95% of the stock of Silence Therapeutics is held by insiders.Percentage Held by Institutions98.73% of the stock of Silence Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Silence Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Silence Therapeutics are expected to grow in the coming year, from ($1.55) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Silence Therapeutics is -16.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Silence Therapeutics is -16.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSilence Therapeutics has a P/B Ratio of 3.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Silence Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Silence Therapeutics Stock (NASDAQ:SLN)Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.Read More SLN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLN Stock News HeadlinesSeptember 5 at 2:18 PM | seekingalpha.comSilence: Additional siRNA Drug Data Leads To Next Stages Of DevelopmentSeptember 4 at 4:13 AM | americanbankingnews.comSilence Therapeutics (NASDAQ:SLN) Coverage Initiated by Analysts at Jefferies Financial GroupSeptember 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 31, 2024 | americanbankingnews.comSilence Therapeutics' (SLN) Buy Rating Reaffirmed at HC WainwrightAugust 27, 2024 | businesswire.comSilence Therapeutics to Webcast Presentations at Upcoming September Investor ConferencesAugust 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Silence Therapeutics Amid Strong Pipeline Progress and Strategic PartnershipsAugust 16, 2024 | benzinga.comAnalyst Expectations For Silence Therapeutics's FutureAugust 16, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: MiNK Therapeutics (INKT), Silence Therapeutics (SLN) and Mersana Therapeutics (MRSN)September 7, 2024 | Porter & Company (Ad)War on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.August 15, 2024 | investorplace.comSLN Stock Earnings: Silence Therapeutics Reported Results for Q2 2024August 15, 2024 | finanznachrichten.deSilence Therapeutics plc: Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 15, 2024 | stockhouse.comSilence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsAugust 7, 2024 | investorplace.comThe 3 Best Gene Editing Stocks to Buy in August 2024July 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Danaher (DHR), Silence Therapeutics (SLN) and Exscientia Plc (EXAI)June 24, 2024 | businesswire.comSilence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma CollaborationJune 21, 2024 | seekingalpha.comSilence Therapeutics: PV Data For Consideration After ASCVD Treatment ResultsJune 20, 2024 | businesswire.comSilence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)May 30, 2024 | businesswire.comSilence Therapeutics to Present at Jefferies Global Healthcare ConferenceSee More Headlines Receive SLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/15/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLN CUSIPN/A CIK1479615 Webwww.silence-therapeutics.com Phone44-0-20-3457-6900FaxN/AEmployees100Year Founded1999Price Target and Rating Average Stock Price Target$57.20 High Stock Price Target$75.00 Low Stock Price Target$40.00 Potential Upside/Downside+206.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,820,000.00 Net Margins-222.44% Pretax Margin-258.08% Return on Equity-58.28% Return on Assets-27.77% Debt Debt-to-Equity RatioN/A Current Ratio9.83 Quick Ratio9.83 Sales & Book Value Annual Sales$31.55 million Price / Sales17.69 Cash FlowN/A Price / Cash FlowN/A Book Value$4.74 per share Price / Book3.93Miscellaneous Outstanding Shares29,930,000Free Float29,045,000Market Cap$558.19 million OptionableNot Optionable Beta1.29 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Craig A. Tooman M.B.A. (Age 59)President, CEO & Executive Director Comp: $1.49MMs. Rhonda L. Hellums (Age 51)CFO & Secretary Comp: $907.23kDr. Steven J. Romano M.D. (Age 65)Head of Research & Development Comp: $662.65kDr. Marie Wikstrom Lindholm Ph.D.Chief Scientific OfficerMs. Gem Gokmen HopkinsHead of IR & Corporate CommunicationsDr. Barbara A. Ruskin J.D. (Age 63)Ph.D., Senior VP and Chief Intellectual Property & Innovation Officer Dr. Eric Floyd M.B.A. (Age 61)M.S., Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance Mr. J.P. GabrielChief Technical Operations OfficerMr. Curtis Rambaran M.D.Chief Medical OfficerMore ExecutivesKey CompetitorsVerona PharmaNASDAQ:VRNABausch Health CompaniesNYSE:BHCApogee TherapeuticsNASDAQ:APGEGemini TherapeuticsNASDAQ:GMTXVera TherapeuticsNASDAQ:VERAView All CompetitorsInstitutional OwnershipPoint72 Asset Management L.P.Bought 138,300 shares on 8/19/2024Ownership: 0.490%Quarry LPBought 6,000 shares on 8/16/2024Ownership: 0.020%Millennium Management LLCBought 373,523 shares on 8/15/2024Ownership: 2.616%Lombard Odier Asset Management USA CorpBought 17,086 shares on 8/14/2024Ownership: 8.039%Marshall Wace LLPBought 10,206 shares on 8/14/2024Ownership: 0.499%View All Institutional Transactions SLN Stock Analysis - Frequently Asked Questions How have SLN shares performed this year? Silence Therapeutics' stock was trading at $17.37 at the beginning of the year. Since then, SLN stock has increased by 7.4% and is now trading at $18.65. View the best growth stocks for 2024 here. How were Silence Therapeutics' earnings last quarter? Silence Therapeutics plc (NASDAQ:SLN) posted its earnings results on Thursday, August, 15th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.10. The business earned $0.76 million during the quarter, compared to the consensus estimate of $11.28 million. Silence Therapeutics had a negative trailing twelve-month return on equity of 58.28% and a negative net margin of 222.44%. Who are Silence Therapeutics' major shareholders? Silence Therapeutics' top institutional shareholders include Lombard Odier Asset Management USA Corp (8.04%), Millennium Management LLC (2.62%), First Turn Management LLC (1.80%) and SG Americas Securities LLC (1.15%). How do I buy shares of Silence Therapeutics? Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
